<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Severe <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>), characterised by elevated serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels, is a known complication in the first 3 weeks after peripheral blood stem cell transplantation (PBSCT) </plain></SENT>
<SENT sid="1" pm="."><plain>Severe <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> is associated with capillary leakage and multiple organ dysfunction and leads to high mortality </plain></SENT>
<SENT sid="2" pm="."><plain>We report a 17-year-old male, who developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> with capillary leakage (CL) after allogeneic PBSCT </plain></SENT>
<SENT sid="3" pm="."><plain>The patient presented with a maximum serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> of 25.4 mg/dl, <z:mp ids='MP_0005456'>weight gain</z:mp> (10% of baseline weight), <z:hpo ids='HP_0007430'>generalized edema</z:hpo>, <z:e sem="disease" ids="C1392046" disease_type="Disease or Syndrome" abbrv="">cardiovascular insufficiency</z:e>, complement activation, <z:hpo ids='HP_0000952'>jaundice</z:hpo> and a decreased AT and protein C functional activity </plain></SENT>
<SENT sid="4" pm="."><plain>After <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> and CL were diagnosed the patient was treated with recombinant human plasminogen activator (rt-PA) and C1 esterase-inhibitor concentrate (C1-INH-C) </plain></SENT>
<SENT sid="5" pm="."><plain>The clinical symptoms resolved and the patient's status stabilized </plain></SENT>
<SENT sid="6" pm="."><plain>The patient was in an adequate clinical state 5 months after transplantation </plain></SENT>
<SENT sid="7" pm="."><plain>We noted that the combined therapy with rt-PA and C1-INH-C in this high-risk situation led to a resolution of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e> with CL </plain></SENT>
</text></document>